https://hibercell.com/
Home - HiberCell
Apr 30, 2026 - Developing therapies targeting adaptive-stress driven vulnerabilities to combat treatment resistance, cancer relapse, and metastasis.
https://www.globenewswire.com/news-release/2025/05/27/3088667/0/en/HiberCell-Announces-Successful-Completion-of-Dose-Escalation-and-Enrollment-Update-for-Ph1b-Study-Evaluating-HC-7366-in-Combination-with-WELIREG-belzutifan-in-Advanced-ccRCC.html
HiberCell Announces Successful Completion of Dose
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse,...
announcessuccessfulcompletiondose